5 results about "Interstitial pneumonia" patented technology

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention provides a method and a system for diagnosing interstitial pneumonia after new crown infection by using multi-modal fusion, which are combined with multi-modal data (text, image and inspection), extract clinical text features by using BERT, process image information by combining Swin-Transform, and perform multi-modal feature fusion through a dynamic fusion learning algorithm, so that the diagnosis precision and specificity are remarkably improved, and the diagnosis accuracy and the diagnosis specificity are improved. According to the method, the limitation of traditional single-mode analysis is broken through, compared with a single-mode diagnosis method, the diagnosis accuracy of a multi-mode fusion model on a test set is improved by about 15%, misdiagnosis and missed diagnosis are reduced, and through automatic and objective AI diagnosis, misdiagnosis and missed diagnosis conditions caused by human factors are reduced.

The present application relates to the technical field of pharmaceutical preparations, in particular to a powder aerosol intermediate composition and a preparation method thereof, a sodium ciprofloxacin inhalation powder aerosol and an application thereof. The raw and auxiliary materials of the intermediate composition include 1-7 wt% of sodium ciprofloxacin, 92-98 wt% of lactose and not more than 1% of magnesium stearate, in terms of mass percentage fraction; the D 50 of the sodium ciprofloxacin is 1-5 microns; the D 50 of the lactose is 100-150 microns. The intermediate composition can be used for preparing the sodium ciprofloxacin inhalation powder aerosol, and can realize efficient delivery of the sodium ciprofloxacin, improve the delivery efficiency of the sodium ciprofloxacin at a target site, and reduce systemic side effects. The sodium ciprofloxacin inhalation powder aerosol can be used for treating mild diseases such as cystic fibrosis, interstitial pneumonia and idiopathic pulmonary fibrosis, and thus expands the indications of the sodium ciprofloxacin.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a Huihui decoction and application thereof in treating interstitial pneumonia. The Huhui decoction is prepared from radix bupleuri, radix paeoniae rubra, fructus aurantii immaturus, fructus perillae, rhizoma pinelliae, cortex magnoliae officinalis, apricot kernels and radix glycyrrhizae, has the effects of soothing the liver, regulating the lung and promoting qi to activate blood and can be used for treating various symptoms such as liver depression, lung closure, qi stagnation and blood stasis. Clinical practices show that the traditional Chinese medicine composition can be added or reduced along with symptoms on the basis of the traditional Chinese medicine composition, can effectively relieve clinical symptoms of ILD patients, and has a good application prospect. Animal experiments prove that the loopback decoction has a definite overall treatment effect on multi-phenotype abnormalities such as joint inflammation and pulmonary function impairment of RA-ILD mice, and can effectively improve joint inflammation, pulmonary fibrosis and abnormal inflammatory response caused by RA-ILD.

The invention provides a pharmaceutical composition. The pharmaceutical composition is prepared from benidipine, folic acid substances and acceptable auxiliary materials. The ratio range of the benidipine to the folic acid is (2-10): (0.2-2.0) according to the content of the benidipine and the folic acid. The pharmaceutical composition has the advantages that the pharmaceutical composition can inhibit pulmonary fibrosis, can be provided for pulmonary fibrosis high-risk groups such as pulmonary tuberculosis, chronic bronchitis, interstitial pneumonia and silicosis, and is used for preventing or treating pulmonary fibrosis. In addition, the compound form of the pharmaceutical composition is beneficial to improving the curative effect, reducing the side effect and increasing the medication compliance.